However , in preplanned analyses , overall survival was significantly longer for patients with del@-positive tumours in the afatinib group than in the chemotherapy group in both trials : in LUX-Lung @ , median overall survival was @ months ( @ % CI @-@ @ ) in the afatinib group versus @ months ( @-@ @ ) in the chemotherapy group ( HR @ , @ % CI @-@ @ , p = @ ) ; in LUX-Lung @ , it was @ months ( @ % CI @-@ @ ) versus @ months ( @-@ @ ) , respectively ( HR @ , @ % CI @-@ @ , p = @ ) .